SCHEMBL15415151

SCHEMBL15415151

O=C(O)C1CCN(c2ncc(B(O)O)cn2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.64
CYP2C19 P33261 1/20 0.64
HSD17B10 Q99714 2/20 0.51
USP2 O75604 1/20 0.51
HPGD P15428 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
NEK2 P51955 3/20 0.50
LMNA P02545 1/20 0.42
HTT P42858 1/20 0.42
AOC3 Q16853 1/20 0.42
NOTUM Q6P988 4/20 0.41
RIPK1 Q13546 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
PPARG P37231 1/20 0.39
ATM Q13315 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15415370 0.82 KDM4E (0.54) KDM4ECYP2C19HPGDNEK2LMNA
SCHEMBL16909894 0.82 KDM4E (0.56) KDM4ECYP2C19HSD17B10HPGDNPSR1
SCHEMBL16909483 0.82 KDM4E (0.56) KDM4ECYP2C19HSD17B10HPGDNPSR1
SCHEMBL15415025 0.82 KDM4E (0.56) KDM4ECYP2C19HSD17B10HPGDNPSR1
SCHEMBL12716919 0.81 KDM4E (0.68) KDM4ECYP2C19HSD17B10USP2HPGD
SCHEMBL3875517 0.81 KDM4E (0.68) KDM4ECYP2C19HSD17B10USP2HPGD
SCHEMBL15751660 0.81 KDM4E (0.68) KDM4ECYP2C19HSD17B10USP2HPGD
SCHEMBL18248384 0.81 KDM4E (0.68) KDM4ECYP2C19HSD17B10USP2HPGD
SCHEMBL16909366 0.80 POLB (0.43) KDM4ECYP2C19HSD17B10USP2HPGD
SCHEMBL18150782 0.80 SMO (0.40) KDM4ECYP2C19LMNAHTTAOC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3080127-B1 IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2020-06-24 EP disclosed
EP-3080130-B1 TRIAZOLOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SRL (BE) 2020-06-03 EP disclosed
EP-3080109-B1 TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-05-15 EP disclosed
EP-3080116-B1 PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-05-08 EP disclosed
US-10273238-B2 Indazolones as modulators of TNF signaling ABBVIE INC. (US) 2019-04-30 US disclosed
EP-2872511-B1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2019-01-16 EP disclosed
US-10160748-B2 Indazolones as modulators of tnf signaling ABBVIE INC. (US) 2018-12-25 US disclosed
EP-2872508-B1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2018-08-29 EP disclosed
US-10053464-B2 Triazolopyridazine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-08-21 US disclosed
US-20180215764-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING ABBVIE INC. 2018-08-02 US disclosed
WO-2015086508-A1 BENZOTRIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086496-A1 TRIAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086502-A1 PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles UCB BIOPHARMA SPRL (BE) 2015-06-04 US disclosed
EP-2872511-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
EP-2872508-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
EP-2858983-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB Biopharma SPRL (BE) 2015-04-15 EP disclosed
WO-2014009295-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed
WO-2014009296-A1 IMIDAZOPYRAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed
WO-2013186229-A1 TNF -ALPHA MODULATING BENZIMIDAZOLES UCB PHARMA S.A. (BE) 2013-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152065-A1 TNF -Alpha Modulating Benzimidazoles TNF, TNFRSF1A, NFKBIA KDM4E 3916/4885CYP2C19 1792/4885HSD17B10 3895/4885
US-10053464-B2 Triazolopyridazine derivatives as modulators of TNF activity TNF, TNFRSF1A, NFKBIA KDM4E 4346/4885CYP2C19 659/4885HSD17B10 3821/4885
US-20180215764-A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING TNF, TNFRSF9, TNFRSF1A KDM4E 4258/4885CYP2C19 293/4885HSD17B10 3500/4885
US-10160748-B2 Indazolones as modulators of tnf signaling TNF, CD40, TNFRSF1A KDM4E 4111/4885CYP2C19 744/4885HSD17B10 3581/4885
US-10273238-B2 Indazolones as modulators of TNF signaling TNF, TNFRSF9, TNFRSF1A KDM4E 4258/4885CYP2C19 293/4885HSD17B10 3500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.